Drugdiscovery >> Drugs >> News
7053
Views
Boehringer Ingelheim’s lung cancer drug afatinib (Giotrif ) approved in Europe - drugdiscovery.com
Boehringer Ingelheim’s lung cancer drug afatinib (Giotrif ) approved in Europe - drugdiscovery.com


The European Commission has granted marketing authorization for afatinib, used as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).
Read More >>


Tags: Giotrif, afatinib, locally advanced, metastatic, non-small cell lung cancer, NSCLC, EGFR mutation, EU, Europe - September 27, 2013
Related Articles
3044
Views
Gilotrif tables will soon be available in US Gilotrif tables will soon be available in US
Gilotrif tablets for oral use will be commercially available in the US the week of September 2nd. Boehringer Ingelheim ‘s drug Gilotrif (afatinib) has been approved by the FDA in July as a new first Read More >>

Tags: Gilotrif, afatinib, tablets, Boehringer Ingelheim , commercially available, non-small cell, lung cancer, metastatic

4764
Views
 Afatinib  is beneficial  for patients with distinct subtype of lung cancer Afatinib is beneficial for patients with distinct subtype of lung cancer
The results of LUX-Lung phase III trial show that Afatinib delays tumour growth and improves disease-related symptoms in patients with EGFR mutation positive, advanced non-small cell lung cancer (NSC Read More >>

Tags: Afatinib, lung cancer, EGFR mutation

6074
Views
First biosimilar mAb therapy approved in Europe First biosimilar mAb therapy approved in Europe
Hospira’s Inflectra, monoclonal antibody (mAb) therapy, a biosimilar to Remicade (infliximab), has been approved by the European Commission (EC) for the treatment of inflammatory conditions includin Read More >>

Tags: Hospira, Inflectra, infliximab, Remicade, biosimilar, monoclonal antibody, inflamatory conditions, treatment, Europe

5681
Views
Gilotrif Approved for Late-Stage Lung Cancer Gilotrif Approved for Late-Stage Lung Cancer
The U.S. Food and Drug Administration approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth Read More >>

Tags: Gilotrif, metastatic non-small cell lung cancer

10375
Views
Another Sanofi MS drug approved in EU Another Sanofi MS drug approved in EU
After Aubagio, Lemtrada - another Sanofi’s drug for treatment of multiple sclerosis has been approved by the European Commission. Read More >>

Tags: multiple sclerosis, Europe, new drug, Aubagio, Lemtrada

5820
Views
Gilotrif Approved by FDA to Target Lung Cancer Gilotrif Approved by FDA to Target Lung Cancer
The U.S. Food and Drug Administration has approved a new drug that has been linked to treat lung cancer. Gilotrif (afatinib) has been approved for use and treatment for patients with a specific sub-ty Read More >>

Tags: Gilotrif, lung cancer, cancer, cure

15324
Views
Breakthrough therapy designation for Roche’s lung cancer drug alectinib Breakthrough therapy designation for Roche’s lung cancer drug alectinib
The FDA has granted breakthrough therapy designation for Roche’s promising investigational 2nd generation ALK inhibitor, used for the treatment of patients with metastatic non-small cell lung cance Read More >>

Tags: alectinib, lung cancer, breakthrough therapy designation, Roche, investigational drug, ALK inhibitor, metastatic non-small cell lung cancer, NSCLC, FDA

11968
Views
New drug for treating myeloma approved in Europe New drug for treating myeloma approved in Europe
The European Commission has granted approval for Celgene’s drug pomalidomide for the treatment of relapsed and refractory multiple myeloma, in combination with dexamethasone. The marketing name of Read More >>

Tags: Celgene, pomalidomide, multiple myeloma,Imnovid,the European Commission approval

5970
Views
 Pfizer’s perosnalized medicine drug for lung cancer not recommended by NICE Pfizer’s perosnalized medicine drug for lung cancer not recommended by NICE
Xalkori (crizotinib) should be used as a later line treatment of ALK positive, advanced non small cell lung cancer (NSCLC) patients. NICE has acknowledged that the drug may offer better outcomes comp Read More >>

Tags: Xalkori, crizotinib, advanced, non small cell lung cancer, NICE

8155
Views
Takeda's schizophrenia drug lurasidone approved in Swiss Takeda's schizophrenia drug lurasidone approved in Swiss
This is the first approval in Europe for lurasidone, which is already marketed as Latuda for schizophrenia and bipolar depression in the US and Canada. Read More >>

Tags: lurasidone, latuda, drug, schizophrenia, bipoloar disorder, Swiss, approval, Europe

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013